LncRNA MALAT1 Promotes the Proliferation, Migration, and Invasion of Melanoma Cells by Downregulating miR-23a
Open accessAbstract
PURPOSE: This study was designed to investigate the relationship between long-chain non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (lncRNA MALAT1)/miR-23a-23a and melanoma. PATIENTS AND METHODS: Fifty-two cases of corresponding non-tumor normal tissues and 109 cases (including 62 cases of primary melanoma and 47 cases of metastatic melanoma) were collected. Real-time fluorescent PCR quantified lncRNA MALAT1 and miR-23a, and counted the 3-year survival of high/low miR-23 and high/low lncRNA MALAT1 populations. We predicted the binding site according to the sequence information of lncRNA MALAT1 and miR-23a. lncRNA MALAT1 siRNA and miR-23a mimics vectors were constructed and transfected into melanoma cell lines respectively to observe their effects on cells. RESULTS: Compared with corresponding non-tumor normal tissues, lncRNA MALAT1 in melanoma tissue increased while miR-23a decreased. Compared with primary melanoma, metastatic melanoma was higher and miR-23a was lower. Downregulation of lncRNA MALAT1 caused upregulation of miR-23a, and lncRNA MALAT1 could bind to miR-23a. Downregulating lncRNA MALAT1 or upregulating miR-23a inhibited cell proliferation, migration and invasion and promoted apoptosis. Rescue experiments revealed that downregulation of miR-23a could offset cell changes caused by downregulation of lncRNA MALAT1. CONCLUSION: lncRNA MALAT1 promotes malignant proliferation of melanoma cells through miR-23a.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Downregulation of Malat1 or MEG3 leads to an increase in miR-23a levels, consequently promoting tumor cell proliferation, migration, and invasion.
“A downregulation of Malat1 or MEG3 leads to an increase in miR-23a levels, consequently promoting tumor cell proliferation, migration, and invasion [100,101].”
From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [100]
The Abstract (Results; page not specified) reports that MALAT1 downregulation raises miR-23a levels but inhibits, rather than promotes, melanoma-cell proliferation, migration, and invasion. The Results section on miR-23a confirms that increasing miR-23a inhibits these behaviors. The supplied passages do not address MEG3. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn melanoma and pituitary tumors, miR-23a binds to lncRNA Malat1 and MEG3.
“in melanoma and pituitary tumors, miR-23a binds to lncRNA Malat1 and MEG3.”
From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [100]
The Results section (“miR-23a is the Target Gene of lncRNA MALAT1”; page unavailable) reports sequence pairing and a luciferase assay supporting MALAT1–miR-23a binding in melanoma cells. The paper does not report this interaction with MEG3 in pituitary tumors; its References section mentions a MEG3–miR-23a study in laryngeal cancer instead. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Epidemiology and Risk Factors of Melanoma
Carr, S. A., Smith, C., & Wernberg, J. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.005 · Cited by 365 · see citing works
Racial disparities in melanoma survival
Dawes, S. M., Tsai, S., Gittleman, H. R., Barnholtz‐Sloan, J. S., & Bordeaux, J. S. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.06.006 · Cited by 197 · see citing works
Malakar, P., Stein, I., Saragovi, A., Winkler, R., Stern‐Ginossar, N., Berger, M., Pikarsky, E., & Karni, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1432 · Cited by 193 · see citing works
Melanoma Epidemiology and Prevention
Berwick, M., Buller, D. B., Cust, A. E., Gallagher, R. P., Lee, T. K., Meyskens, F. L., Pandey, S., Thomas, N. E., Veierød, M. B., & Ward, S. V. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_2 · Cited by 152 · see citing works
Gordon, M. A., Babbs, B. L., Cochrane, D. R., Bitler, B. G., & Richer, J. K. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22919 · Cited by 125 · see citing works
Yu, W., Ding, J., He, M., Chen, Y., Wang, R., Han, Z., Xing, E. Z., Zhang, C., & Yeh, S. (2018) · Oncogene · doi:10.1038/s41388-018-0463-1 · Cited by 117 · see citing works
Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study
Ghiasvand, R., Weiderpass, E., Green, A. C., Lund, E., & Veierød, M. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5934 · Cited by 116 · see citing works
MALAT1 long non-coding RNA and breast cancer
Arun, G., & Spector, D. L. (2019) · RNA Biology · doi:10.1080/15476286.2019.1592072 · Cited by 110 · see citing works
Melanoma pathology reporting and staging
Scolyer, R. A., Rawson, R. V., Gershenwald, J. E., Ferguson, P. M., & Prieto, V. G. (2019) · Modern Pathology · doi:10.1038/s41379-019-0402-x · Cited by 109 · see citing works
Xi, Z., Si, J., & Nan, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4609 · Cited by 104 · see citing works
Serum overexpression of miR-301a and miR-23a in patients with colorectal cancer
Karimi, N., Feizi, M. A. H., Safaralizadeh, R., Hashemzadeh, S., Baradaran, B., Shokouhi, B., & Teimourian, S. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000031 · Cited by 87 · see citing works
Horizontal transfer of miR‐23a from hypoxic tumor cell colonies can induce angiogenesis
Sruthi, T. V., Edatt, L., Raji, G. R., Kunhiraman, H., Shankar, S. S., Shankar, V., Ramachandran, V., Poyyakkara, A., & Kumar, V. B. S. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26202 · Cited by 83 · see citing works
Zhang, X., Wu, N., Wang, J., & Li, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14549 · Cited by 77 · see citing works
miR-23a promotes invasion of glioblastoma via HOXD10-regulated glial-mesenchymal transition
Yachi, K., Tsuda, M., Kohsaka, S., Wang, L., Oda, Y., Tanikawa, S., Ohba, Y., & Tanaka, S. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0033-6 · Cited by 69 · see citing works
Genetic epidemiology of melanoma
Ribero, S., Glass, D., & Bataille, V. A. (2016) · European Journal of Dermatology · doi:10.1684/ejd.2016.2787 · Cited by 65 · see citing works
Ma, M., Dai, J., Tang, H., Xu, T., Yu, S., Si, L., Cui, C., Sheng, X., Chi, Z., Mao, L., et al. (2019) · Theranostics · doi:10.7150/thno.30516 · Cited by 65 · see citing works
Sun, Y. J., Cheng, H., Wang, G., Yu, G., Zhang, D., Wang, Y., Fan, W., & Yang, W. (2016) · Oncotarget · doi:10.18632/oncotarget.13862 · Cited by 60 · see citing works
NEAT1/miR-23a-3p/KLF3: a novel regulatory axis in melanoma cancer progression
Ding, F., Lai, J., Gao, Y., Wang, G., Shang, J., Zhang, D., & Zheng, S. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0927-6 · Cited by 59 · see citing works
MALAT1 regulates miR-34a expression in melanoma cells
Li, F., Li, X., Qiao, L., Liu, W., Xu, C., & Wang, X. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1620-3 · Cited by 54 · see citing works
Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.
Tian, R., Liu, T., Li, Q., Gao, M. H., & Li, J. (2015) · PubMed Central · Cited by 54 · see citing works
Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma
Armand-Labit, V., Meyer, N., Casanova, A., Bonnabau, H., Platzer, V., Tournier, É., Sansas, B., Verdun, S., Thouvenot, B., Hilselberger, B., et al. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-2156 · Cited by 53 · see citing works
Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk
Rachakonda, P. S., Kong, H.-Y., Srinivas, N., García‐Casado, Z., Requena, C., Fallah, M., Heidenreich, B., Planelles, D., Traves, V., Schadendorf, D., et al. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22669 · Cited by 50 · see citing works
Chien, M., Lee, W.-J., Yang, Y., Li, Y.-L., Chen, B.-R., Cheng, T., Yang, P.-W., Wang, M.-Y., Jan, Y., Lin, Y., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2017.08.005 · Cited by 49 · see citing works
Self-citationXie, J., Li, W. H., Li, X., Ye, W., & Shao, C. (2019) · PubMed · Cited by 48 · see citing works
Malignant melanoma in HIV: Epidemiology, pathogenesis, and management
Facciolà, A., Rullo, E. V., Ceccarelli, M., D’Andrea, F., Coco, M., Micali, C., Cacopardo, B. S., Marıno, A., Cannavò, S. P., Rosa, M. D., et al. (2019) · Dermatologic Therapy · doi:10.1111/dth.13180 · Cited by 47 · see citing works
microRNA-10b is a prognostic biomarker for melanoma
Saldanha, G. S., Elshaw, S. R., Sachs, P., Alharbi, H., Shah, P., Jothi, A., & Pringle, J. H. (2016) · Modern Pathology · doi:10.1038/modpathol.2015.149 · Cited by 43 · see citing works
Chopra, A., Sharma, R. R., & Rao, U. N. M. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.004 · Cited by 37 · see citing works
Azevedo‐Barbosa, H., Ferreira‐Silva, G. Á., Silva, C. F., de Souza, T. B., Dias, D. F., de Paula, A. C. C., Ionta, M., & Carvalho, D. T. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.04.023 · Cited by 35 · see citing works
MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer
Tang, Z., Fang, Y., & Du, R. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.009 · Cited by 24 · see citing works
miR-488-5p and its role in melanoma
Arnold, J., Engelmann, J. C., Schneider, N., Bosserhoff, A., & Kuphal, S. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104348 · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs.
Ginckels, P., & Holvoet, P. (2022) · PubMed Central · Cited by 67 · see citing works
MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy
Bitaraf, A., Zafarani, A., Jahandideh, P., Hakak‐Zargar, B., Haghi, A., Asgaritarghi, G., & Babashah, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02415-6 · Cited by 30 · see citing works
Current understanding of functional peptides encoded by lncRNA in cancer
Tian, H., Tang, L., Yang, Z., Xiang, Y., Min, Q., Yin, M., You, H., Xiao, Z., & Shen, J. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03446-7 · Cited by 25 · see citing works
Zhang, J., Liu, H., Zhang, W., Li, Y., Fan, Z., Jiang, H., & Luo, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.615671 · Cited by 25 · see citing works
Self-citationZhao, W., Yin, Y., Cao, H., & Wang, Y. (2021) · Cardiology Research and Practice · doi:10.1155/2021/8840698 · Cited by 22 · see citing works
The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma
Zhou, W., Xu, X., Cen, Y., & Chen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1085766 · Cited by 20 · see citing works
Wu, L., Li, K., Lin, W., Liu, J., Qi, Q., Shen, G., Chen, W., & He, W. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00313-9 · Cited by 18 · see citing works
Long non-coding RNAs and melanoma: From diagnosis to therapy
Dashti, F., Mirazimi, S. M. A., Kazemioula, G., Mohammadi, M. R., Hosseini, M., Bahabadi, Z. R., Mirazimi, M. S., Abadi, M. H. J. N., Shahini, A., Afshari, M., et al. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154232 · Cited by 16 · see citing works
Xu, J., Ou, R., Nie, G., Wen, J., Ling, L., Mo, L., Xu, R., Lv, M., Zhao, L., Lai, W., et al. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000803 · Cited by 13 · see citing works
Lin, Q., Jia, Y., Zhang, D., & Jin, H. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02055-y · Cited by 12 · see citing works
LncRNAs in melanoma phenotypic plasticity: emerging targets for promising therapies
Tonin, B. C. B., de Sousa, C.-S. C., John, S. F., & Jasiulionis, M. G. (2024) · RNA Biology · doi:10.1080/15476286.2024.2421672 · Cited by 9 · see citing works
Pathogenic roles of long noncoding RNAs in melanoma: Implications in diagnosis and therapies
Xiao, Y., Xia, Y., Wang, Y., & Xue, C. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.007 · Cited by 8 · see citing works
Cong, L., Zhao, Q., Sun, H., Zhou, Z., Hu, Y., Li, C., Hao, M., & Cong, X. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01922-7 · Cited by 8 · see citing works
Hong, A., Cao, M., Li, D., Wang, Y., Zhang, G., Fang, F., Zhao, L., Wang, Q., Lin, T., & Wang, Y. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad073 · Cited by 7 · see citing works
Liao, S., He, J., Liu, C., Zhang, Z., Liao, H., Liao, Z.-W., Yu, C., Guan, J., Mo, H., Yuan, Z., et al. (2021) · Medicine · doi:10.1097/md.0000000000026219 · Cited by 7 · see citing works
Zhang, P., Liu, X., Pan, G., Xu, J., Shen, B., Ding, X., & Lv, W.-L. (2022) · BioMed Research International · doi:10.1155/2022/3546795 · Cited by 6 · see citing works
RetractedLncRNA OR2A1‐AS1 index predicts survival in germinal center‐like diffuse large B‐cell lymphoma
Ye, S., Ying, W., Lin, Y., Hou, Z., & Su, M. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24680 · Cited by 6 · see citing works
Recent advances of miR-23 in human diseases and growth development
Qian, X., Jiang, Y., Yang, Y., Zhang, Y., Xu, N., Xu, B., Pei, K., Yu, Z., & Wu, W. (2025) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.12.010 · Cited by 5 · see citing works
Tsai, K., Liao, J.-B., & Tseng, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03545-5 · Cited by 4 · see citing works
Silent Players, Loud Impact: The Influence of lncRNAs on Melanoma Progression
Kiełbowski, K., Ćmil, M., Dach, A., Cole, A., Jerzyńska, O., Bakinowska, E., Plewa, P., & Pawlik, A. (2025) · Cancers · doi:10.3390/cancers17244033 · Cited by 3 · see citing works
Long noncoding RNA MALAT1 in dermatologic disorders: a comprehensive review
Ruiz-Ojeda, D., Guzmán-Martín, C. A., Bojalil, R., Flores-Balderas, X., Paredes-González, I. S., González-Ramírez, J., Torres‐Rasgado, E., Hernández-Díazcouder, A., Springall, R., & Sánchez‐Muñoz, F. (2024) · Biomarkers in Medicine · doi:10.1080/17520363.2024.2369044 · Cited by 3 · see citing works
Naghibi, A. F., Taha, S. R., Zadeh, M. S., Daneshdoust, D., Bagheri, K. H., Farkhondeh, T., Samini, M., Pourhanifeh, M. H., & Samarghandian, S. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096329727250129173510 · Cited by 3 · see citing works
Zhou, X., Wen, M., Zhang, J., Long, K., Lu, L., Jin, L. G., Sun, J., Ge, L., Li, X., Li, M., et al. (2024) · Cells · doi:10.3390/cells13141198 · Cited by 3 · see citing works
A symphony of signals: the intricate role of lncRNAs in dermatological disorders
Vanan, A. G., Nouri, S., Hassanzadeh, F., Taghizadeh-Anvar, M., Naeij, M. H., Varghaei, A., & Tahmasebi, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01957-9 · Cited by 2 · see citing works
Zhang, J., Xue, Y., Gao, H., Yun-xi, Y., Cheng, H., Lv, X., & Ke, K. (2022) · BioMed Research International · doi:10.1155/2022/7386946 · Cited by 1 · see citing works
RetractedZhao, W., Yin, Y., Cao, H., & Wang, Y. (2021) · Microvascular Research · doi:10.1016/j.mvr.2021.104194
RetractedLin, Q., Jia, Y., Zhang, D., & Jin, H. (2021) · Figshare · doi:10.6084/m9.figshare.14956028
Lin, Q., Jia, Y., Zhang, D., & Jin, H. (2021) · Figshare · doi:10.6084/m9.figshare.14956031
Lin, Q., Jia, Y., Zhang, D., & Jin, H. (2021) · Figshare · doi:10.6084/m9.figshare.14956025
- Authors
- Wang, P., Hu, L., Fu, G., Lu, J., Zheng, Y., Li, Y., & Jia, L.
- Affiliations
- Wuhan Children's Hospital (CN)
- Hubei Cancer Hospital (CN)
- Central Hospital of Wuhan (CN)
- Corresponding author
- Li, Ying
- Venue
- Cancer Management and Research
- Publisher
- Informa UK Limited
- Published
- 2020-07
- Volume
- Volume 12
- Pages
- 6553-6562
- ISSN
- 1179-1322 (ISSN-L)
- PMC
- PMC7397564
- OpenAlex
- W3045628124
- Cited by
- 29
- References
- 30
- Citations by year
- 2025: 4 · 2024: 7 · 2023: 1 · 2022: 7 · 2021: 9 · 2020: 1
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancer Management and Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- MALAT1, miR-23a, melanoma, metastatic melanoma, cell proliferation, cell migration, cell invasion, apoptosis, lncRNA-miRNA interaction, microRNA downregulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
